These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11078305)

  • 1. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
    Dujovne CA; Harris WS; Altman R; Overhiser RW; Black DM
    Am J Cardiol; 2000 Feb; 85(3):350-3. PubMed ID: 11078305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
    Szapáry L; Horváth B; Márton Z; Fehér G; Tóth K; Komoly S
    Orv Hetil; 2008 Jun; 149(24):1117-23. PubMed ID: 18539578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
    Otto C; Geiss HC; Donner MG; Parhofer KG; Schwandt P
    Ther Apher; 2000 Jun; 4(3):244-8. PubMed ID: 10910028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic effects of atorvastatin versus simvastatin.
    Kadikoylu G; Yukselen V; Yavasoglu I; Bolaman Z
    Ann Pharmacother; 2003 Apr; 37(4):478-84. PubMed ID: 12659599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia.
    Empen K; Geiss HC; Lehrke M; Otto C; Schwandt P; Parhofer KG
    Nutr Metab Cardiovasc Dis; 2003 Apr; 13(2):87-92. PubMed ID: 12929621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling.
    Goudevenos JA; Bairaktari ET; Chatzidimou KG; Milionis HJ; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2001; 16(4):269-75. PubMed ID: 11268711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
    Sasaki S; Kuwahara N; Kunitomo K; Harada S; Yamada T; Azuma A; Takeda K; Nakagawa M
    Am J Cardiol; 2002 Feb; 89(4):386-9. PubMed ID: 11835916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
    Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.
    Bolaman Z; Kadikoylu G; Ozgel N; Yenisey C
    J Natl Med Assoc; 2006 Aug; 98(8):1273-7. PubMed ID: 16916124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.
    Trifiletti A; Lasco A; Scamardi R; Pizzoleo MA; Gaudio A; La Rocca R; Morini E; Frisina N
    Pathophysiol Haemost Thromb; 2003; 33(2):84-7. PubMed ID: 14624049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.